KBC Group NV Has $264,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

KBC Group NV boosted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 55.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,950 shares of the medical equipment provider’s stock after buying an additional 1,052 shares during the quarter. KBC Group NV’s holdings in Lantheus were worth $264,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in LNTH. Groupama Asset Managment bought a new stake in Lantheus in the third quarter worth about $439,000. Janus Henderson Group PLC raised its holdings in shares of Lantheus by 7.7% in the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock worth $393,844,000 after purchasing an additional 257,022 shares during the period. Massachusetts Financial Services Co. MA purchased a new position in Lantheus in the third quarter valued at approximately $25,955,000. Point72 DIFC Ltd bought a new position in Lantheus during the third quarter valued at $23,001,000. Finally, Swedbank AB increased its position in Lantheus by 21.1% in the third quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock worth $79,266,000 after buying an additional 125,843 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on LNTH. Truist Financial reiterated a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. JMP Securities reiterated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, The Goldman Sachs Group began coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $131.86.

Lantheus Stock Down 3.2 %

Lantheus stock opened at $89.54 on Tuesday. The business has a 50-day simple moving average of $92.03 and a 200 day simple moving average of $99.33. Lantheus Holdings, Inc. has a 52 week low of $52.96 and a 52 week high of $126.89. The stock has a market cap of $6.23 billion, a price-to-earnings ratio of 14.90 and a beta of 0.44.

Insider Transactions at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.10% of the stock is owned by insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.